The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) and The Michael J. Fox Foundation (MJFF) have announced a new US$5 million partnership to accelerate the development of minimally invasive biomarkers for measuring pathologies associated with Parkinson’s and Alzheimer’s diseases. Isobel Coleman, Chief Executive Officer of the Alzheimer’s Drug Discovery… Read More
Lario Therapeutics has received a total of $2.4 million in grant funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Wellcome to support the continued expansion of its neuronal calcium channel drug discovery platform. With the proceeds of these awards, Lario is expanding its… Read More
French biotech Lys Therapeutics has received a grant award of $5 million (£3.6 million) from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to accelerate the clinical development of its first-in-class monoclonal antibody for the treatment of Parkinson’s disease and other neurodegenerative disorders. The funding… Read More
Herantis Pharma has dosed the first patients in the final cohort of its Phase Ib clinical trial evaluating the safety and tolerability of HER-096 in patients with Parkinson’s disease. Commenting on the study, Antti Vuolanto, CEO of Herantis Pharma, said: “Parkinson’s disease is a life altering condition, and there is… Read More
NRG Therapeutics has been awarded a $5 million grant from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support the development of NRG5051 as a novel disease-modifying treatment for Parkinson’s disease. The company says NRG5051 also has potential in other neurological diseases such as… Read More
SandboxAQ is collaborating with the University of Dundee in the UK to improve its inhibitor for the gene most commonly associated with Parkinson’s disease (PD). The company has signed a $25 million research grant through The Michael J Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative… Read More
Biopharmaceutical company Lario Therapeutics has been awarded a $6 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to fund Lario’s preclinical programme investigating selective CaV2.3 calcium channel inhibition as a novel and disease-modifying approach for treatment of… Read More
Mission Therapeutics has been awarded $5.2 million from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK. The funding will help advance Mission’s potential disease-modifying treatment for Parkinson’s disease (PD), MTX325. MTX325 is a potent, selective, small molecule brain-penetrant USP30… Read More
Alchemab Therapeutics has been awarded a grant of $595,000 by The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease (PD) programme. The grant will fund research performed at Alchemab following its identification of antibodies that target prostaglandin biology in PD, a potentially unique… Read More
